Aikaterini Kaloudi

Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results

Berthold A. Nock, Aikaterini Kaloudi, Emmanouil Lymperis et al. · Journal of Nuclear Medicine · 2016 · 167 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients

Mark Konijnenberg, Petra Kolenc Peitl, Piotr Garnuszek et al. · European Journal of Pharmaceutical Sciences · 2016 · 50 citations · Full text

Medicine, Nuclear Medicine, Pharmacokinetics +17

Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin

Emmanouil Lymperis, Aikaterini Kaloudi, Werner Sallegger et al. · Bioconjugate Chemistry · 2018 · 38 citations

Medicine, Nuclear Medicine, Oncology +17

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice

Aikaterini Kaloudi, Emmanouil Lymperis, Athina Giarika et al. · Molecules · 2017 · 35 citations · Full text

Medicine, Oncology, Pharmacology +16

[99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes

Berthold A. Nock, Aikaterini Kaloudi, Panagiotis Kanellopoulos et al. · Cancers · 2021 · 35 citations · Full text

Medicine, Nuclear Medicine, Oncology +17